Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA polymerase/reverse transcriptase

3

Human immunodeficiency virus type 1 reverse transcriptase

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1995

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic hepatitis B

3

HIV-1 infection

3

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Belleau, B.|Nguyen-Ba, N.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

3

CAS

2

PUBCHEM

2

CHEBI

1

ChEMBL

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIVIRALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DIRECT ACTING ANTIVIRALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antivirals for treatment of HIV infections, combinations

1

Nucleoside and nucleotide reverse transcriptase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LAMIVUDINE

2T8Q726O95

Export Data
Search for Structure

Status:

US Approved Rx (1995)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA polymerase/reverse transcriptase

Human immunodeficiency virus type 1 reverse transcriptase

Conditions:

HIV-1 infection

Chronic hepatitis B

Lamivudine is a reverse transcriptase inhibitor used alone or in combination with other classes of anti-human immunodeficiency virus (HIV) drugs in the treatment of HIV infection. This molecule has two stereo-centers, thus giving rise to four stereoi...

somers: (+/-)-cis-lamivudine and (+/-)-trans-lamivudine. The latter is considered to be impurity of the pharmaceutically active isomer, (-)-cis-lamivudine.

LAMIVUDINE, (±)-TRANS-

77ANF82R6X

Export Data
Search for Structure

Status:

US Approved Rx (1995)

First approved in 1995

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

DNA polymerase/reverse transcriptase

Human immunodeficiency virus type 1 reverse transcriptase

Conditions:

HIV-1 infection

Chronic hepatitis B

Lamivudine is a reverse transcriptase inhibitor used alone or in combination with other classes of anti-human immunodeficiency virus (HIV) drugs in the treatment of HIV infection. This molecule has two stereo-centers, thus giving rise to four stereoi...

somers: (+/-)-cis-lamivudine and (+/-)-trans-lamivudine. The latter is considered to be impurity of the pharmaceutically active isomer, (-)-cis-lamivudine.

LAMIVUDINE METHANOL SOLVATE

PEM7E7C913

Export Data
Search for Structure

Status:

US Approved Rx (1995)

First approved in 1995

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA polymerase/reverse transcriptase

Human immunodeficiency virus type 1 reverse transcriptase

Conditions:

HIV-1 infection

Chronic hepatitis B

Lamivudine is a reverse transcriptase inhibitor used alone or in combination with other classes of anti-human immunodeficiency virus (HIV) drugs in the treatment of HIV infection. This molecule has two stereo-centers, thus giving rise to four stereoi...

somers: (+/-)-cis-lamivudine and (+/-)-trans-lamivudine. The latter is considered to be impurity of the pharmaceutically active isomer, (-)-cis-lamivudine.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1